Diary - News
All news Focus on ImmunID
Grenoble, France, January 21, 2015 — ImmunID, an immune molecular diagnostics company, announced today the enrolment of the first five patients in its PREDICT-ID Melanoma study to assess the predictive value of immune profiles for response to Ipilimumab®, an immunomodulatory agent.
One month after receiving authorization from the French regulatory bodies for the PREDICT-ID study, ImmunID is delighted to announce that the first two clinical centers, in Lyon and Angers, have recruited five metastatic melanoma patients. These two hospitals will be shortly followed by six additional renowned French c
